Across the past 12 months, open-market trades by Alterity Therapeutics insiders were all purchases, totaling $23,810 (47.62K shares).
| # | Insider | Position | Direct | Indirect | Total | Share of Insiders | Last Filed |
|---|---|---|---|---|---|---|---|
| 1 | Peter Ashley Marks | Director | 0 | 191,340 | 191,340 | 100.0% | 08 Sep, 2026 |
Each row is that insider’s most recently reported position, from Form 4 filings over the last 60 months — which is why this total does not tie to the quarterly series above, where a quarter counts only the insiders who filed in it. Shares held through a fund or institutional portfolio are counted on the institutional ownership page instead.
| Date | Insider | Position | Transaction | Shares | Price | Value | Shares Held After | Ownership |
|---|---|---|---|---|---|---|---|---|
| 31 Aug, 2026 | David Allen Stamler | Chief Executive Officer | Disposed P | 47,620 | $0.50 | $23.81K | 0 | Direct |
| 31 Aug, 2026 | Peter Ashley Marks | Director | Acquired P | 47,620 | $0.50 | $23.81K | 191,340 | Indirect |
| 31 Aug, 2026 | Peter Ashley Marks | Director | Disposed P | 47,620 | $0.50 | $23.81K | 0 | Indirect |
| 15 Jun, 2026 | Julian Michael Babarczy | Director | Acquired A | 2,000,000 | $0.00 | $0 | 2,000,000 | Indirect |
| 15 Jun, 2026 | Lawrence Bernard Gozlan | Director | Acquired A | 1,000,000 | $0.00 | $0 | 1,000,000 | Indirect |